1. Home
  2. EIC vs BWAY Comparison

EIC vs BWAY Comparison

Compare EIC & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EIC

Eagle Point Income Company Inc.

HOLD

Current Price

$9.98

Market Cap

250.4M

Sector

Finance

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$24.06

Market Cap

450.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EIC
BWAY
Founded
N/A
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Finance/Investors Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
250.4M
450.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EIC
BWAY
Price
$9.98
$24.06
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$14.00
$26.50
AVG Volume (30 Days)
166.9K
79.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
13.32%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$9.27
$314.08
Revenue Next Year
N/A
$23.37
P/E Ratio
$9.08
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$9.78
$7.84
52 Week High
$16.05
$26.63

Technical Indicators

Market Signals
Indicator
EIC
BWAY
Relative Strength Index (RSI) 36.33 52.86
Support Level $9.78 $14.79
Resistance Level $11.34 $25.71
Average True Range (ATR) 0.24 1.39
MACD 0.00 -0.15
Stochastic Oscillator 31.08 35.03

Price Performance

Historical Comparison
EIC
BWAY

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: